Osimertinib in Patients with T790M Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. We present results of a subgroup analysis of Korean patients from the pooled data of two global phase II trials: AURA extension [NCT01802632] and AURA2 [NCT02094261]). Enrolled patients had EGFR T790M positive NSCLC and disease progression during or after EGFR-TKI therapy. Patients received osimertinib 80 mg orally once daily until disease progression. The primary endpoint was objective response rate (ORR). In total, 66 Korean patients received osimertinib treatment with a median treatment duration of 19 months. In the evaluable-for-response population (EFR) (n=62), ORR was 74% (95% confidence interval [CI], 61.5-84.5) and median duration of response was 9.8 months (95% CI, 7.1-16.8). In the full analysis set (n=66), median progression-free survival was 10.9 months (95% CI, 8.3-15.0; data cutoff November 1, 2016) and median overall survival was 29.2 months (95% CI 24.8-35.7; data cutoff May 1, 2018). Eight patients with CNS metastases were evaluable for response, none of whom showed CNS progression. The most common adverse events were rash (53%), cough (33%), paronychia, diarrhoea and decreased appetite (each 32%). Efficacy and safety profiles of osimertinib in this subgroup are consistent with the global phase II pooled population, which supports osimertinib as a recommended treatment for Korean patients with T790M positive NSCLC.